Zobrazeno 1 - 10
of 58
pro vyhledávání: '"J. Rothenstein"'
Autor:
J. Jolivet, Frances A. Shepherd, F. Romeyer, N. Finn, J. Villeneuve, J. Rothenstein, Rosalyn A. Juergens, A. Faghih, S. Owen, Catherine Labbé, Caroline Mariano, Charles Butts, M.N. Reaume, Filippa Pettersson
Publikováno v:
Current Oncology
Volume 25
Issue 6
Pages 4287-392
Volume 25
Issue 6
Pages 4287-392
Nivolumab was the first immuno-oncology agent available for the treatment of lung cancer in Canada. In the present study, we evaluated the real-world benefit of nivolumab in Canadian patients with lung cancer. Patients included in the cohort were ide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2a1b63762501b05e76926fd8f9c8c1b
https://doi.org/10.3747/co.25.4287
https://doi.org/10.3747/co.25.4287
Autor:
S. Effendi, Lisa W. Le, J. Law, M. Chan, H. Albaba, K. M. Pisters, P. A. Bradbury, S. Gill, Natasha B. Leighl, J. Rothenstein, Tong Zhang, U. Zurawska, Dianne Zawisza, M. Trinkaus, S. Arif, Tracey L. Stockley, Donna M. Graham, Andrea S. Fung, M. Sawczak, Eric X. Chen
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 157
Introduction MEK inhibition is a potential therapeutic strategy in non-small cell lung cancer (NSCLC). This phase I study evaluates the MEK inhibitor binimetinib plus carboplatin and pemetrexed in stage IV non-squamous NSCLC patients (NCT02185690). M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e67470ded1d8aeca0ac3711c18b5c30c
https://pubmed.ncbi.nlm.nih.gov/34052705
https://pubmed.ncbi.nlm.nih.gov/34052705
Autor:
Toru Kumagai, A. Alexandru, Michael Schenker, Yuichiro Ohe, P. Ruff, M. Nishio, A. Tomiak, P. Lowry, I. Gore, I. Ntambwe, J. Rothenstein, Toyoaki Hida, Natasha B. Leighl, S. Marimuthu
Publikováno v:
Journal of Thoracic Oncology. 16:S949-S950
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d5f944efee83b8fe21f74f98ab75147
https://doi.org/10.1016/j.jtho.2021.08.215
https://doi.org/10.1016/j.jtho.2021.08.215
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Duncan J. Stewart, David Roberge, Robert MacRae, Shantanu Banerji, Janessa Laskin, Stephanie Brule, Scott A. Laurie, Garth Nicholas, P. Cheung, Vera Hirsh, Rosalyn A. Juergens, Natasha B. Leighl, Ming-Sound Tsao, Parneet Cheema, N. Daaboul, J. Rothenstein, Desiree Hao, N. Blais
Publikováno v:
Current Oncology
Volume 26
Issue 1
Pages 4116-93
Volume 26
Issue 1
Pages 4116-93
Background: Little evidence has been generated for how best to manage patients with non-small-cell lung cancer (NSCLS) presenting with rarer clinical scenarios, including oligometastases, oligoprogression, and pseudoprogression. In each of those scen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e757632054c6ccc64595d3e776113cbc
https://pubmed.ncbi.nlm.nih.gov/30853813
https://pubmed.ncbi.nlm.nih.gov/30853813
Publikováno v:
Current Oncology
Volume 26
Issue 1
Pages 4096-42
Volume 26
Issue 1
Pages 4096-42
For more than a decade, there has been no improvement in outcomes for patients with unresectable locally advanced (la) non-small-cell lung cancer (nsclc). The standard treatment in that setting is definitive concurrent chemotherapy and radiation (ccr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4fd9d26715779d515a663b0743b4e70
https://europepmc.org/articles/PMC6380636/
https://europepmc.org/articles/PMC6380636/
Autor:
J. Rothenstein, N. Chooback
Publikováno v:
Current Oncology
Volume 25
Issue 11
Pages 3760-67
Volume 25
Issue 11
Pages 3760-67
The treatment of advanced non-small-cell lung cancer (NSCLC) has undergone a paradigm shift since the early 2000s. The identification of molecular subtypes of the disease, based on oncogenic drivers, has led to the development of personalized medicin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e7753bdb869c72cb862986555a1700f
https://pubmed.ncbi.nlm.nih.gov/29910648
https://pubmed.ncbi.nlm.nih.gov/29910648
Autor:
N. Finn, D. Sauciuc, J. Yun, L. Musallam, J. Rothenstein, Rosalyn A. Juergens, Vera Hirsh, K. Marquis, Ang Li, P. Begin, Quincy Chu, A. Acevedo, A. Faghih, F. De Angelis, Shantanu Banerji, Parneet K. Cheema
Publikováno v:
Journal of Thoracic Oncology. 12:S2426-S2427
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ebf7986d98bb3ee69969c9165b0cc38
https://doi.org/10.1016/j.jtho.2017.11.088
https://doi.org/10.1016/j.jtho.2017.11.088
Autor:
J. Rothenstein, Alexander I. Spira, Vamsidhar Velcheti, Julien Mazieres, C.A. Thomas, Wei Yu, M. Gandhi, Geetha Shankar, Ronald B. Natale, J. Goldschmidt, Anthony Lee, W. Lin, Michael P. Kosty, Mark Kozloff, S. Ponce Aix
Publikováno v:
Journal of Thoracic Oncology. 13:S495
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce5e615bf4ae4d6b189010ab7406bed5
https://doi.org/10.1016/j.jtho.2018.08.639
https://doi.org/10.1016/j.jtho.2018.08.639
Autor:
Barbara Melosky, Randeep Sangha, Duncan J. Stewart, Natasha B. Leighl, K. Papp, J. Rothenstein
Targeting the epidermal growth factor receptor (EGFR) pathway has become standard practice for the treatment of advanced non-small-cell lung cancer. Compared with chemotherapy, EGFR tyrosine kinase inhibitors (TKIS) have been associated with improved
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d32aa592ccda4adeee1b13e9418f519
https://europepmc.org/articles/PMC4399609/
https://europepmc.org/articles/PMC4399609/